Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 3213-3220

  Koumakis, Eugénie ^a,b   Souberbielle, Jean Claude ^b,c   Sarfati, Emile ^d   Meunier, Marine ^a   Maury, Emilie ^a   Gallimard, Elizabeth ^a   Borderie, Didier ^a   Kahan, André ^a   Cormier, Catherine ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; VITAMIN D;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIP; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PARATHYROID ADENOMA; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; POSTOPERATIVE PERIOD; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SPINE; TREATMENT RESPONSE;

AGED; BONE DENSITY; CALCIUM; COHORT STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PARATHYROIDECTOMY; VITAMIN D;

EID: 84881494368     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1518     Document Type: Article

References (33)

1. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249-1255.
2. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008;93(9):3462-3470.
3. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 1989;4:283-291.
4. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80:729-734.
5. Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study. Bone. 1999; 25(5):589-595.
6. Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone. 1999;25(2):237-244.
7. Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2008;68(5):707-715.
8. Leppla DC, Snyder W, Pak CY. Sequential changes in bone density before and after parathyroidectomy in primary hyperparathyroidism. Invest Radiol. 1982;17:604-606.
9. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007;3114-3121.
10. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007;92(50):1687-1692.
11. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004;89(11):5415-5422.
12. Silverberg SJ, Bilezikian JP, Bone HG, Talpos GB, Horwitz MJ, Stewart AF. Therapeutic controversies in primary hyperparathyroidism. J Clin Endocrinol Metab. 1999;84:2275-2285.
13. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009:94(20):351-365.
14. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013;16:33-39.
15. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007; 92(8):3001-3005.
16. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003; 88:4641-4648.
17. Eisner BH, Ahn J, Stoller ML. Differentiating primary from secondary hyperparathyroidism in stone patients: the "thiazide challenge." J Endourol. 2009;191-192.
18. Coe FL, Canterbury JM, Firpo JJ, Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest. 1973;23(2):52:134-142.
19. Monchik JM, Lamberton RP, Roth U. Role of the oral calciumloading test with measurement of intact parathyroid hormone in the diagnosis of symptomatic subtle primary hyperparathyroidism. Surgery. 1992;112(6):1103-1109; discussion 1109-1110.
20. Broadus AE, Horst RL, Littledike ET, Mahaffey JE, Rasmussen H. Primary hyperparathyroidism with intermittent hypercalcaemia: serial observations and simple diagnosis by means of an oral calcium tolerance test. Clin Endocrinol (Oxf). 1980;12:225-235.
21. Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S. Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J Clin Endocrinol Metab. 1989;68:654-660.
22. Balsa JA, Botella-Carretero JI, Peromingo R, et al. Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Invest. 2008; 31(10):845-850.
23. Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res. 1999;14:652-657.
24. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with onceweekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20:141-151.
25. Nordenstrom E, Westerdahl J, Bergenfelz A. Recovery of bone mineral density in 126 patients after surgery for primary hyperparathyroidism. World J Surg. 2004;28:502-507.
26. Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine. 2012;42:764-766.
27. Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery. 1997;121:287-294.
28. Wade TJ, Yen TW, Amin AL, Wang TS. Surgical management of normocalcemic primary hyperparathyroidism. World J Surg. 2012; 36:761-766.
29. Mann GB, Kang YC, Brand C, Ebeling PR, Miller JA. Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol. 2009;27(22):3605-3610.
30. Camacho PM, Dayal AS, Diaz JL, et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol. 2008;26(33):5380-5385.
31. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf). 2008;69(1):1-19.
32. Elvius M, Lagrelius A, Nygren A, Alveryd A, Christensson TA, Nordenstrom J. Seventeen year follow-up study of bone mass in patients with mild asymptomatic hyperparathyroidism some of whom were operated on. Eur J Surg. 1995;161:863-869.
33. Fraser WD. Hyperparathyroidism. Lancet 2009;374(9684): 145-158.